FEATURE STORY ● AllergoOncology: microbiota in allergy and cancer - an EAACI position paper BASIC SCIENCE ● The 1000IBD project: multi-omics data of 1000 inflammatory bowel disease patients ● Effect of the nursing mother on the gut microbiome of the offspring during early mouse development ● Enhancement of the gut barrier integrity by…..
An inhalable form of mRNA for the treatment of lung diseases About 80 RNA therapeutics are currently in clinical trial. Among these drug candidates, mRNA, which can induce cells to produce therapeutic proteins, holds great promise for treating a variety of diseases. The biggest obstacle to this approach so far…..
BioPharmAnalyses is proud to announce the launch of the first issue of its "BRIEFING ON RNA TRIALS" This 86-page document provides you an accurate overview to explore the latest trials in the RNA therapeutics area. « BRIEFING ON RNA TRIALS » gives you a breakdown of trials: • by…..
The European Medicine Agency (EMA) is launching a six-month public consultation on its draft ‘ Regulatory Science to 2025’ strategy for a six-month public consultation. This sixty-page document proposes the plan for advancing the Agency’s engagement with regulatory science over the next five to ten years, covering both human and veterinary medicines. The…..
Sepsis is an overreaction of the body's immune system to an infection. Cytokines flood the bloodstream in an attempt to fight the infection but also cause blood vessels to become leaky. White blood cells escape from the vessels, causing inflammation and damage to surrounding tissue, ultimately leading to multi-organ failure…..
Cancer develops as a result of the accumulation of mutations in cells. These mutations are not distributed evenly in chromosomes, so some regions hold more than others. A study headed by Institute for Research in Biomedicine (IRB Barcelona) researchers Salvador Aznar Benitah and Fran Supek examined whether the opening of…..
The International Society for Cell and Gene Therapy (ISCT), the global professional society of clinicians, researchers, regulatory specialists, technologists and industry partners in the cell and gene therapy sector, has published its first annual report detailing global cell and gene therapies (CGT) with market authorization. This report is intended to provide…..
Un entretien avec Régine Rouzier, présidente de la CRO Cap Research Quel élément central conditionne la réussite d’une étude de phase I ? La réussite d’une étude de phase I passe par la rapidité dans l’exécution et par la qualité du travail rendu. Ce sont les deux piliers fondamentaux d’un…..
An interview with Régine Rouzier, president of the CRO Cap Research What is the central issue to successfully perform a phase I trial? The success of a phase I study depends on the speed in execution and the excellence and quality of returned work. These are the two fundamental pillars…..
- 1
- 2
- 3
...
- 33
- Page Suivante
Partenaires
